50289-12-8

Usage

Uses

Used in Pharmaceutical Industry:
4-AMINOTETRAHYDRO-2H-PYRAN-4-CARBONITRILE is used as a chemical intermediate for the synthesis of various pharmaceutical drugs. Its unique structure and properties make it a valuable component in the development of new medications.
Used in Drug Discovery and Development:
As a compound with demonstrated anti-inflammatory and analgesic properties, 4-AMINOTETRAHYDRO-2H-PYRAN-4-CARBONITRILE is used in drug discovery and development efforts to create novel therapeutic agents that can address various medical conditions.
Used in Medicinal Chemistry Research:
4-AMINOTETRAHYDRO-2H-PYRAN-4-CARBONITRILE is utilized as a building block in the synthesis of new drug molecules, contributing to the advancement of medicinal chemistry and the discovery of innovative pharmaceutical compounds.

InChI:InChI=1/C6H10N2O/c7-5-6(8)1-3-9-4-2-6/h1-4,8H2

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 519031-87-9 tert-butyl (4-cyanotetrahydro-2H-pyran-4-yl)carbamate 
• 848821-06-7 4-cyanotetrahydro-2H-pyran-4-carboxylic acid 
• 38041-19-9 4-aminotetrahydropyran 
• 7677-24-9 trimethylsilyl cyanide 
• 773837-37-9 sodium cyanide 

Downstream Products

• 39124-20-4 4-aminotetrahydro-2H-pyran-4-carboxylic acid 
• 184698-41-7 4-aminotetrahydropyran-4-carboxylicacid methyl ester 
• 720706-20-7 (4-aminotetrahydro-2H-pyran-4-yl)methanol 
• 50289-16-2 4-(aminomethyl)tetrahydro-2H-pyran-4-amine 
• 176445-77-5 4-(dimethylamino)tetrahydro-2H-pyran-4-carbonitrile 
• 1284281-42-0 1-(2-bromophenyl)-N-(4-cyanotetrahydro-2H-pyran-4-yl)-5-phenyl-1H-pyrazole-3-carboxamide 
• 1284281-61-3 1-(2-bromophenyl)-N-(4-cyanotetrahydro-2H-pyran-4-yl)-5-(3-fluorophenyl)-4-methyl-1H-pyrazole-3-carboxamide 
• 1284281-60-2 1-(2-bromophenyl)-N-(4-cyanotetrahydro-2H-pyran-4-yl)-5-(4-fluorophenyl)-4-methyl-1H-pyrazole-3-carboxamide 
• 1284281-59-9 4-bromo-1-(3-bromophenyl)-N-(4-cyanotetrahydro-2H-pyran-4-yl)-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxamide 
• 1284281-52-2 N-(4-cyanotetrahydro-2H-pyran-4-yl)-1-(2-phenylphenyl)-4-methyl-5-phenyl-1H-pyrazole-3-carboxamide 
• 1284281-51-1 N-(4-cyanotetrahydro-2H-pyran-4-yl)-1-(2-iodophenyl)-4-methyl-5-phenyl-1H-pyrazole-3-carboxamide 
• 1284281-50-0 1-(4-bromophenyl)-N-(4-cyanotetrahydro-2H-pyran-4-yl)-4-methyl-5-phenyl-1H-pyrazole-3-carboxamide 
• 1284281-49-7 1-(3-bromophenyl)-N-(4-cyanotetrahydro-2H-pyran-4-yl)-4-methyl-5-phenyl-1H-pyrazole-3-carboxamide 
• 1284281-48-6 1-(2-bromophenyl)-4-cyano-N-(4-cyanotetrahydro-2H-pyran-4-yl)-5-phenyl-1H-pyrazole-3-carboxamide 

Relevant academic research and scientific papers

2,3-DIHYDRO-1H-PYRROLIZINE-7-FORMAMIDE DERIVATIVE AND APPLICATION THEREOF

The present application relates to a 2,3-dihydro-1H-pyrrolizine-7-formamide derivative as a nucleoprotein inhibitor and a use in preparation of a drug for treating HBV related diseases. The present application specifically relates to a compound represented by formula (II), and isomers or pharmaceutically acceptable salts thereof.

Preparation method of heterocyclic compound and salt thereof

The invention belongs to the field of organic chemistry and specifically relates to a preparation method of a heterocyclic compound as shown in the formula I and salt thereof. In comparison with the prior art, the invention has the following beneficial effects: the use of the extremely toxic substance cyanide is avoided; there is no cyanide ion residue in the reaction product and the reaction waste such that environmental burden is greatly reduced. In addition, the price of the reaction materials is low; the preparation method is simple; the yield is high; and the preparation method is suitable for large-scale industrial production. It is found unexpectedly that by the adoption of the method of the scheme 4, such as use of a reducing agent and under the acidic condition, the compound VIIIcan be obtained by one-step reaction and the off-protecting group, alkylation and cyano group reduction are realized to obtain the target product. The defect that polystep reactions are required in the prior art is greatly improved.

Primary α-tertiary amine synthesis via α-C-H functionalization

A quinone-mediated general synthetic platform for the construction of primary α-tertiary amines from abundant primary α-branched amine starting materials is described. This procedure pivots on the efficient in situ generation of reactive ketimine intermediates and subsequent reaction with carbon-centered nucleophiles such as organomagnesium and organolithium reagents, and TMSCN, creating quaternary centers. Furthermore, extension to reverse polarity photoredox catalysis enables reactivity with electrophiles, via a nucleophilic α-amino radical intermediate. This efficient, broadly applicable and scalable amine-to-amine synthetic platform was successfully applied to library and API synthesis and in the functionalization of drug molecules.

PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS

This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER

This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

Design and Synthesis of Fsp3-Rich, Bis-Spirocyclic-Based Compound Libraries for Biological Screening

The exploration of innovative chemical space is a critical step in the early phases of drug discovery. Bis-spirocyclic frameworks occur in natural products and other biologically relevant metabolites and show attractive features, such as molecular compactness, structural complexity, and three-dimensional character. A concise approach to the synthesis of bis-spirocyclic-based compound libraries starting from readily available commercial reagents and robust chemical transformations has been developed. A number of novel bis-spirocyclic scaffold examples, as implemented in the European Lead Factory project, is presented.

3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS

The invention provides certain 3-pyridyl carboxamide-containing compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS

The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

Compounds useful as reversible inhibitors of cysteine proteases

Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.